In this randomised controlled trial, the researchers looked at the effects of oral teriflunomide on MS pathology by MRI. 1088 RRMS patients were randomised to teriflunomide 7mg or 24mg once daily or placebo for 108 weeks.
The primary endpoint was annualised relapse rate and secondary outcomes included confirmed progression of disability. The main MRI outcome was change in total lesion volume. Total lesion volume was 67.4% and 39.4% lower in the 14mg and 7mg dose groups versus placebo.
Overall, teriflunomide showed favourable outcomes on brain MRI activity on several measures, with a dose effect evident on several markers. These results complement the clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression.
Authors: Wolinsky JS, Narayana PA, Nelson F
Source: Mult Scler. 2013 Feb 27. [Epub ahead of print]
Read the abstract